Symbio Pharmaceuticals Limited (4582) Price & Analysis

4582 Stock Chart & Stats

¥44.00-¥2.00(-4.35%)

At close: Oct 30 4:00 PM EDT

Day’s Range: JPY 44.00 - JPY 46.00
52-Week Range: JPY 44.00 - JPY 229.00
Previous Close: JPY 46.00
Volume: 398.00K
Average Volume (3M): 530.21K
Market Cap: JPY 3.72B
Enterprise Value: JPY 5.25B
Total Cash (Recent Filing): JPY 977.18M
Total Debt (Recent Filing): JPY 832.50M
Price to Earnings (P/E): ―
Beta: 0.82
Next Earnings: Feb 11, 2027
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Specialty Pharma Focus

Concentration in oncology and hematology gives SymBio a defined specialty-pharmaceutical positioning rather than a broad, undifferentiated portfolio. This focus can support targeted clinical development, regulatory expertise, and deeper commercial knowledge over the next several quarters.

High Gross Margin

A high gross margin indicates that marketed or developed products retain favorable economics before operating expenses. Although current costs prevent profitability, preserving product-level margin provides a foundation for improved earnings if revenue stabilizes or operating spending becomes more efficient.

Product Expansion Model

The ability to pursue additional indications and use external manufacturing or licensing counterparties creates multiple avenues to develop the portfolio. This model can extend product opportunities and broaden commercialization potential without relying solely on one development pathway.

Bears Say

Revenue Contraction

Multi-year revenue contraction signals weakening commercial performance rather than a single temporary fluctuation. Continued top-line pressure can reduce the resources available for clinical development and commercialization, making recovery in profitability and cash generation more difficult.

Persistent Losses

The shift to deeply negative operating and net margins shows that current revenue is not covering the company’s broader cost base. Persistent losses can erode equity, constrain investment capacity, and increase dependence on financing while management works to restore sustainable profitability.

Cash Burn And Leverage

Negative operating and free cash flow mean the business is not funding itself from operations, while increased debt and a shrinking equity base reduce financial flexibility. If cash burn persists, external financing needs may remain elevated and could constrain strategic execution.

Symbio Pharmaceuticals Limited News

SymBio Pharmaceuticals Swings to Deep Negative Equity as Losses Mount in 2026

Symbio Pharmaceuticals Limited ( ($JP:4582) ) just unveiled an update. SymBio Pharmaceuticals reported a sharp deterioration in its financial position for the first nine months of 2026, with net sales

3d ago4582

SymBio’s First-Half Loss Deepens as Equity Turns Negative

An update from Symbio Pharmaceuticals Limited ( ($JP:4582) ) is now available. SymBio Pharmaceuticals reported a sharp decline in first-half 2026 net sales to ¥469 million, down 27.3% year on

2M ago4582

SymBio Pharma Swings to Negative Equity as Losses Deepen in Q1 2026

Symbio Pharmaceuticals Limited ( ($JP:4582) ) just unveiled an update. SymBio Pharmaceuticals reported first-quarter 2026 consolidated net sales of ¥233 million, down 11.6% year on year, alongside an operating loss

5M ago4582

SymBio’s Phase 3 Antiviral Trial Advances: What Investors Should Watch in NCT07387367

Symbio Pharmaceuticals Limited ($JP:4582) announced an update on their ongoing clinical study. This Phase 3 study, officially titled “A Phase 3, Multicenter, Prospective, Randomized, Open-label Efficacy and Safety Study of

7M ago4582

SymBio’s Brincidofovir Lymphoma Trial Put on Hold: What Investors Need to Know

Symbio Pharmaceuticals Limited ($JP:4582) announced an update on their ongoing clinical study. Study OverviewSymBio Pharmaceuticals is running a global Phase 1b/2 trial called “A Multi-Center, Global, Open-Label, Phase 1b/2 Clinical

8M ago4582

SymBio Pharmaceuticals’ Losses Deepen as Equity Thins Despite 2026 Sales Rebound Forecast

An announcement from Symbio Pharmaceuticals Limited ( ($JP:4582) ) is now available. SymBio Pharmaceuticals reported a steep decline in consolidated net sales for fiscal 2025 to ¥1.31 billion, down 46.7%

8M ago4582

SymBio Pharmaceuticals Reports Significant Financial Decline in 2025

The latest update is out from Symbio Pharmaceuticals Limited ( ($JP:4582) ). SymBio Pharmaceuticals Limited reported a significant decline in financial performance for the first nine months of fiscal year

1y ago4582

SymBio Pharmaceuticals Advances Brincidofovir Study for Lymphoma Treatment

Symbio Pharmaceuticals Limited (($JP:4582)) announced an update on their ongoing clinical study. SymBio Pharmaceuticals Limited is conducting a multi-center, global, open-label Phase 1b/2 clinical study titled ‘A Multi-Center, Global, Open-Label,

1y ago4582

SymBio Pharmaceuticals Reports Significant Financial Losses in H1 2025

Symbio Pharmaceuticals Limited ( ($JP:4582) ) just unveiled an update. SymBio Pharmaceuticals reported a significant decline in financial performance for the first half of 2025, with net sales dropping by

1y ago4582

SymBio Pharmaceuticals Revises 2025 Earnings Forecast Amid Market Shifts

Symbio Pharmaceuticals Limited ( ($JP:4582) ) just unveiled an update. SymBio Pharmaceuticals Limited has revised its earnings forecast for the fiscal year ending December 31, 2025, reflecting a decrease in

1y ago4582

4582 FAQ

What was Symbio Pharmaceuticals Limited’s price range in the past 12 months?

Symbio Pharmaceuticals Limited lowest stock price was ¥44.00 and its highest was ¥229.00 in the past 12 months.

What is Symbio Pharmaceuticals Limited’s market cap?

Symbio Pharmaceuticals Limited’s market cap is ¥3.72B.

When is Symbio Pharmaceuticals Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Symbio Pharmaceuticals Limited’s earnings last quarter?

Symbio Pharmaceuticals Limited released its earnings results on Oct 29, 2026. The company reported -¥15.006 earnings per share for the quarter.

Is Symbio Pharmaceuticals Limited overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Symbio Pharmaceuticals Limited pay dividends?

Symbio Pharmaceuticals Limited does not currently pay dividends.

What is Symbio Pharmaceuticals Limited’s EPS estimate?

Symbio Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Symbio Pharmaceuticals Limited have?

Symbio Pharmaceuticals Limited has 84,548,960 shares outstanding.

What happened to Symbio Pharmaceuticals Limited’s price movement after its last earnings report?

Symbio Pharmaceuticals Limited reported an EPS of -¥15.006 in its last earnings report. Following the earnings report the stock price went down -2.128%.

Which hedge fund is a major shareholder of Symbio Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in JP:4582

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description